Cannabix Technologies Receives Notice of Allowance for Cannabis Drug Detection Device Canadian Patent
April 19, 2021
Vancouver, British Columbia, April 19, 2021 -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (the “Company or Cannabix”) developer of the Cannabix Marijuana Breathalyzer devices for law enforcement and the workplace, reports that it has received a notice of allowance from the Canadian Intellectual Property Office (CIPO) for its 2015 licensed patent application, No. 2887841 entitled, “Cannabis Drug Detection Device”. The Company has been pursuing this original patent application since its filing on April 16, 2015. It should be noted that a notice of allowance from the CIPO does not constitute a grant of patent. The Company will report on future material developments regarding its “Cannabis Drug Detection Device” patent application with CIPO in due course.
Cannabix Technologies is on the forefront in research and development to create point-of-care breath testing technologies for the detection of ∆9-tetrahydrocannabinol (“THC”) - the psychoactive component of marijuana that causes impairment.
The information in these press releases is historical in nature, has not been updated, and is current only to the date indicated in the particular press release. This information may no longer be accurate and therefore you should not rely on the information contained in these press releases. To the extent permitted by law, Cannabix Technologies Inc. and its employees, agents and consultants exclude all liability for any loss or damage arising from the use of, or reliance on, any such information, whether or not caused by any negligent act or omission.